Clinical Trial Update: Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of a trivalent baculovirus-expressed influenza HA vaccine in adults with Non-Hodgkin's B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Trivalent Baculovirus-expressed Influenza HA Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Influenza | Phase 2 | Status: COMPLETED